CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 586 enrolled
Drug / intervention
bimatoprost 0.03% eye drops +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00541242
NCT00541242Phase 4Completed
CompareCT.gov

Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension

Allergan·interventional·Posted Oct 10, 2007·Updated Oct 27, 2011

In Brief

A Phase 4 clinical trial evaluating bimatoprost 0.03% eye drops and latanoprost 0.005% eye drops for Ocular Hypertension and Glaucoma. Completed, enrolled 586 participants across 1 site.

Detailed Summary

The study will compare the safety and efficacy of Bimatoprost and Latanoprost in patients with glaucoma or ocular hypertension

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOcular Hypertension, Glaucoma
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 10, 2007
Enrollment StartDec 1, 2007
Primary CompletionAug 1, 2008
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 18.7 years ago

Interventions

bimatoprost 0.03% eye dropsdrug

Open-labeled latanoprost 0.005% 1 drop into each eye every evening for 6 weeks followed by a masked randomized treatment of bimatoprost 0.03% 1 drop every evening for 12 weeks

latanoprost 0.005% eye dropsdrug

Open-labeled latanoprost 0.005% 1 drop into each eye every evening for 6 weeks followed by a masked randomized treatment of latanoprost 0.005% 1 drop every evening for 12 weeks